Dihydromyricetin Improves Cognitive Impairments in d‐Galactose‐Induced Aging Mice through Regulating Oxidative Stress and Inhibition of Acetylcholinesterase
Scope Alzheimer's disease (AD) is a neurodegenerative disease with phenomena of cognitive impairments. Oxidative stress and cholinergic system dysfunction are two widely studied pathogenesis of AD. Dihydromyricetin (DMY) is a natural dihydroflavonol with many bioactivities. In this study, it is aimed to investigate the effects of DMY on cognitive impairment in d‐galactose ( d‐gal) induced aging mice. Methods and Results Mice are intraperitoneally injected with d‐gal for 16 weeks, and DMY is supplemented in drinking water. The results show that DMY significantly improves d‐gal‐induced cognitive impairments in novel object recognition and Y‐maze studies. H&E and TUNEL staining show that DMY could improve histopathological changes and cell apoptosis in mice brain. DMY effectively induces the activities of catalase, superoxide dismutase and glutathione peroxidase, and reduces malondialdehyde level in mice brain and liver. Furthermore, DMY reduces cholinergic injury by inhibiting the activity of Acetylcholinesterase (AChE) in mice brain. In vitro studies show that DMY is a non‐competitive inhibitor of AChE with IC50 value of 161.2 µg mL−1. Conclusion DMY alleviates the cognitive impairments in d‐gal‐induced aging mice partly through regulating oxidative stress and inhibition of acetylcholinesterase..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Molecular Nutrition & Food Research - 66(2022), 4 |
| Beteiligte Personen: |
Sun, Cui‐Cui [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Wiley‐VCH GmbH |
|---|
| Umfang: |
9 |
|---|
| doi: |
10.1002/mnfr.202101002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY011072628 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY011072628 | ||
| 003 | DE-627 | ||
| 005 | 20230307220046.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230218s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/mnfr.202101002 |2 doi | |
| 028 | 5 | 2 | |a MNFR_MNFR4150.xml |
| 035 | |a (DE-627)WLY011072628 | ||
| 035 | |a (WILEY)MNFR4150 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 630 |a 640 |a 540 |q ASE |
| 082 | 0 | 4 | |a 630 |a 640 |a 540 |q ASE |
| 084 | |a 44.21 |2 bkl | ||
| 084 | |a 58.34 |2 bkl | ||
| 100 | 1 | |a Sun, Cui‐Cui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dihydromyricetin Improves Cognitive Impairments in d‐Galactose‐Induced Aging Mice through Regulating Oxidative Stress and Inhibition of Acetylcholinesterase |
| 264 | 1 | |c 2022 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Wiley‐VCH GmbH | ||
| 520 | |a Scope Alzheimer's disease (AD) is a neurodegenerative disease with phenomena of cognitive impairments. Oxidative stress and cholinergic system dysfunction are two widely studied pathogenesis of AD. Dihydromyricetin (DMY) is a natural dihydroflavonol with many bioactivities. In this study, it is aimed to investigate the effects of DMY on cognitive impairment in d‐galactose ( d‐gal) induced aging mice. Methods and Results Mice are intraperitoneally injected with d‐gal for 16 weeks, and DMY is supplemented in drinking water. The results show that DMY significantly improves d‐gal‐induced cognitive impairments in novel object recognition and Y‐maze studies. H&E and TUNEL staining show that DMY could improve histopathological changes and cell apoptosis in mice brain. DMY effectively induces the activities of catalase, superoxide dismutase and glutathione peroxidase, and reduces malondialdehyde level in mice brain and liver. Furthermore, DMY reduces cholinergic injury by inhibiting the activity of Acetylcholinesterase (AChE) in mice brain. In vitro studies show that DMY is a non‐competitive inhibitor of AChE with IC50 value of 161.2 µg mL−1. Conclusion DMY alleviates the cognitive impairments in d‐gal‐induced aging mice partly through regulating oxidative stress and inhibition of acetylcholinesterase. | ||
| 700 | 1 | |a Yin, Zhong‐Ping |4 aut | |
| 700 | 1 | |a Chen, Ji‐Guang |4 aut | |
| 700 | 1 | |a Wang, Wen‐Jun |4 aut | |
| 700 | 1 | |a Zheng, Guo‐Dong |4 aut | |
| 700 | 1 | |a Li, Jing‐En |4 aut | |
| 700 | 1 | |a Chen, Ling‐Li |4 aut | |
| 700 | 1 | |a Zhang, Qing‐Feng |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular Nutrition & Food Research |g 66(2022), 4 |w (DE-627)WLY011063262 |x 16134133 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2022 |g number:4 |g extent:9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.21 |q ASE |
| 936 | b | k | |a 58.34 |q ASE |
| 951 | |a AR | ||
| 952 | |d 66 |j 2022 |e 4 |g 9 | ||